查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1212095

患者肿瘤组织移植 (PDX) 模式的全球市场

Patient Derived Xenograft / PDX Models
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球患者肿瘤组织移植 (PDX) 模式的市场规模预测将从2022年的1亿3,580万美元，到2030年达到4亿5,690万美元，在2022年～2030年间预计将以16.4％的年复合成长率成长。

本报告提供全球患者肿瘤组织移植 (PDX) 模式市场相关调查分析，提供市场概要，市场趋势，各地区的市场分析，竞争情形等系统性资讯。

调查对像企业范例(计38公司):

  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Epo Berlin-Buch GmbH
  • Hera BioLabs
  • NexusPharma
  • Pharmatest Services Ltd.
  • The Jackson Laboratory
  • WuXi AppTec Co., Ltd.
  • Xentech

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 其他地区

第4章 竞争

简介目录
Product Code: MCP13873

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Patient Derived Xenograft / PDX Models Market to Reach $456.9 Million by 2030

In the changed post COVID-19 business landscape, the global market for Patient Derived Xenograft / PDX Models estimated at US$135.8 Million in the year 2022, is projected to reach a revised size of US$456.9 Million by 2030, growing at aCAGR of 16.4% over the period 2022-2030. Mice Model, one of the segments analyzed in the report, is projected to record 17.7% CAGR and reach US$356.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Rat Model segment is readjusted to a revised 12.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $39.7 Million, While China is Forecast to Grow at 15.2% CAGR

The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$39.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$76 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15% and 13.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Select Competitors (Total 38 Featured):

  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Epo Berlin-Buch GmbH
  • Hera BioLabs
  • NexusPharma
  • Pharmatest Services Ltd.
  • The Jackson Laboratory
  • WuXi AppTec Co., Ltd.
  • Xentech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Patient Derived Xenograft/PDX Models - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Patient Derived Xenograft / PDX Models Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Rat Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for Rat Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Biomarker Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Biomarker Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 19: World 8-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 23: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 25: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • JAPAN
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • CHINA
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 41: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 43: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • EUROPE
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 49: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • FRANCE
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 53: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 55: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • GERMANY
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • UNITED KINGDOM
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 71: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 73: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030

IV. COMPETITION